Cytokinetics has entered an exclusive licensing agreement with Bayer to develop and commercialise aficamten in Japan. The deal announced Tuesday provides Cytokinetics with €70 million in upfront and near-term payments, plus potential milestones up to €490 million, alongside tiered royalties on future sales.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,